Clinical relevance of circulating anti-ENA and anti-dsDNA secreting cells from SLE patients and their dependence on STAT-3 activation

Eur J Immunol. 2017 Jul;47(7):1211-1219. doi: 10.1002/eji.201646872. Epub 2017 May 23.

Abstract

Disturbances of plasma cell homeostasis and auto-antibody production are hallmarks of systemic lupus erythematosus. The aim of this study was to explore the presence of circulating anti-ENA and anti-dsDNA antibody-secreting cells, to determine their dependence on plasma cell-niche cytokines and to analyze their clinical value. The study was performed in SLE patients with serum anti-ENA and/or anti-dsDNA antibodies (n = 57). Enriched B-cell fractions and sorted antibody-secreting cells (CD19low CD38high ) were obtained from blood. dsDNA- and ENA-specific antibody-secreting cells were identified as cells capable of active auto-antibody production in culture. The addition of a combination of IL-6, IL-21, BAFF, APRIL, and CXCL12 to the cultures significantly augmented auto-antibody production and antibody-secreting cell proliferation, whereas it diminished apoptosis. The effect on auto-antibody production was dependent on STAT-3 activation as it was abrogated in the presence of the JAK/STAT-3 pathway inhibitors ruxolitinib and stattic. Among patients with serum anti-dsDNA antibodies, the detection of circulating anti-dsDNA-antibody-secreting cells was associated with higher disease activity markers. In conclusion, auto-antibody production in response to plasma cell-niche cytokines that are usually at high levels in SLE patients is dependent on JAK/STAT-3 activation. Thus, patients with circulating anti-dsDNA antibody-secreting cells and active disease could potentially benefit from therapies targeting the JAK/STAT3 pathway.

Keywords: Anti-ENA; Anti-dsDNA; Antibody-secreting cells; Cytokines; Plasma cell niche; SLE; STAT-3.

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Antibodies, Antinuclear / blood*
  • Antibodies, Antinuclear / immunology
  • Antibody-Producing Cells / drug effects
  • Antibody-Producing Cells / immunology*
  • Apoptosis / drug effects
  • B-Cell Activating Factor / pharmacology
  • Cell Proliferation
  • Chemokine CXCL2 / pharmacology
  • Cyclic S-Oxides / pharmacology
  • DNA / blood
  • DNA / immunology*
  • Female
  • Humans
  • Interleukin-6 / pharmacology
  • Interleukins / pharmacology
  • Lupus Erythematosus, Systemic / blood
  • Lupus Erythematosus, Systemic / immunology*
  • Male
  • Middle Aged
  • Nitriles
  • Pyrazoles / pharmacology
  • Pyrimidines
  • STAT3 Transcription Factor / metabolism*
  • Tumor Necrosis Factor Ligand Superfamily Member 13 / pharmacology
  • Young Adult

Substances

  • Antibodies, Antinuclear
  • B-Cell Activating Factor
  • CXCL2 protein, human
  • Chemokine CXCL2
  • Cyclic S-Oxides
  • Interleukin-6
  • Interleukins
  • Nitriles
  • Pyrazoles
  • Pyrimidines
  • STAT3 Transcription Factor
  • STAT3 protein, human
  • TNFSF13B protein, human
  • Tumor Necrosis Factor Ligand Superfamily Member 13
  • stattic
  • ruxolitinib
  • DNA
  • interleukin-21